Literature DB >> 7547399

Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine.

S Fijan1, H Hönigsmann, B Ortel.   

Abstract

Photodynamic therapy (PDT) uses photosensitizing drugs, such as porphyrins, and light for cancer treatment. In the present clinical study we employed topical application of the porphyrin precursor delta-aminolaevulinic acid (ALA) in combination with desferrioxamine (df) for the induction of endogenous porphyrin synthesis. Irradiation was performed with a light source consisting of a halogen lamp with a red filter and a fibreoptic device. Irradiances ranged from 50 to 300 mW/cm2. We treated 49 patients with this PDT regimen. In 32 patients we treated a total of 34 superficial basal cell carcinomas (BCCs) and 22 nodular BCCs, in nine patients 43 solar keratoses, and in eight patients 10 lesions of Bowen's disease. After a single treatment, 30 (88.2%) of the superficial and seven (31.8%) of the nodular BCCs, 35 of 43 (81.4%) solar keratoses, and three (30%) of the Bowen's disease lesions showed complete remission. The post-treatment observation period was up to 20 months. Repeat therapy was required in six nodular and four superficial BCCs. Biopsies were obtained before treatment, and at variable intervals after treatment. Topical PDT of skin tumours with ALA-df-induced porphyrins is effective in the management of epithelial skin tumours.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547399     DOI: 10.1111/j.1365-2133.1995.tb02630.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

Review 1.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy.

Authors:  Asta Juzeniene; Petras Juzenas; Li-Wei Ma; Vladimir Iani; Johan Moan
Journal:  Lasers Med Sci       Date:  2004-10-16       Impact factor: 3.161

Review 3.  [Photodynamic therapy of cutaneous epithelial malignancies. An evidence-based review].

Authors:  A Sidoroff
Journal:  Hautarzt       Date:  2007-07       Impact factor: 0.751

Review 4.  Photodynamic therapy: a review.

Authors:  J S McCaughan
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

5.  Vitamin D3 enhances the apoptotic response of epithelial tumors to aminolevulinate-based photodynamic therapy.

Authors:  Sanjay Anand; Clara Wilson; Tayyaba Hasan; Edward V Maytin
Journal:  Cancer Res       Date:  2011-08-01       Impact factor: 12.701

6.  Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acid-mediated Protoporphyrin IX by Iron Chelator Deferoxamine.

Authors:  Pratheeba Palasuberniam; Daniel Kraus; Matthew Mansi; Alexander Braun; Richard Howley; Kenneth A Myers; Bin Chen
Journal:  Photochem Photobiol       Date:  2019-03-15       Impact factor: 3.421

Review 7.  Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives.

Authors:  F S De Rosa; M V Bentley
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

8.  Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.

Authors:  Andrew Pye; Sandra Campbell; Alison Curnow
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-01       Impact factor: 4.553

Review 9.  Physical energy for drug delivery; poration, concentration and activation.

Authors:  Shanmugamurthy Lakshmanan; Gaurav K Gupta; Pinar Avci; Rakkiyappan Chandran; Magesh Sadasivam; Ana Elisa Serafim Jorge; Michael R Hamblin
Journal:  Adv Drug Deliv Rev       Date:  2013-06-07       Impact factor: 15.470

Review 10.  Pharmacological treatments for basal cell carcinoma.

Authors:  Seongmu Lee; Dinesh Selva; Shyamala C Huilgol; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.